2022 PDA Annual Meeting

Dallas, TX
Ask a Question Promotional Tools

Health and Safety

The safety and wellbeing of our participants is a top priority for PDA; therefore, we will be implementing the following guidelines for this in-person event:

Vaccination Requirement

Participants, including attendees, exhibitors, trainers, students, staff, guests, contractors, and vendors, must provide proof of vaccination after registering for an in-person event. Accommodation may be offered on a case-by-case basis for any in-person participant who is unable to be vaccinated due to disability or medical condition, or in connection with a sincerely held religious belief or practice, unless otherwise provided under applicable state or local law. Accommodation requests must be made no later than 18 March 2022.

For those registered for the in-person meeting, you will receive a link to upload and verify your vaccine status in early 2022.

Participants that are unable to meet the vaccine requirement or fail to get a PDA-approved accommodation request will not be granted admittance to the event.

Mask Requirement

If mandated by national, state, or local guidelines in effect during the dates of any meeting, PDA will require masks to be worn indoors regardless of vaccination status.

Additional Requirements

PDA will be making decisions on additional precautionary measures closer to the date of the event and in accordance with the latest CDC guidance, local requirements, and hotel policies.

The 2022 PDA Annual Meeting promises to have something for everyone!

This Conference will focus on the theme to Level Up: Agility in the New Normal! We will highlight what’s in store for the future of pharmaceutical manufacturing. Examine how companies are developing new modalities and adapting to the current manufacturing environment through the modernization of aging facilities and the adoption of innovative approaches and processes.

Dive into exciting interactive sessions and tracks especially designed for manufacturing leaders, technical experts/scientists, and early career professionals. No matter what your area of focus, you are sure to come away with tangible, practical solutions to improve your operations and your standing within your company.

Standard Pricing

Standard Member Price

$2,395

Early Career ProfessionalMember Only

$1,195

Non-Member

$2,695

See Qualifying Criteria for Member Types.

GROUP REGISTRATION DISCOUNT: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.

GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.

CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].

Day 1

MONDAY, 04 APRIL

13:00 – 15:00 | P1: Moving Forward from Abrupt Regulatory Challenges to the New Normal
Moderator: Jason Kerr, MBS, MBA, Senior GXP Specialist, Redica Systems

The biopharmaceutical industry has a strong track record of regulatory submissions and approvals. These approvals typically leave folks in industry at the edge of our seats, but the pandemic has since brightened the spotlight for the whole world. Since the announcement of a public health emergency in January 2020, we are gingerly entering our third year with the hopes of a “new normal”. Throughout the years, we have seen changes to regulatory strategies that highlight the use of emergency use authorizations in hopes of thwarting the pandemic. Regulatory agencies have released new policies, flexibilities in procedures, and updates to guidances on the fly, but what are the lasting impact of these changes on our "new normal?”. This session will expand on the regulatory challenges we have endured and how we anticipate the future.

13:00 | Welcome from PDA Leadership and the Program Planning Committee Co-Chairs
Susan J. Schniepp, Distinguished Fellow, Regulatory Compliance Associates Inc. and Chair, PDA Board of Directors
Richard M Johnson, MSc, President and CEO, PDA
Jason Kerr, MBS, MBA, Senior GXP Specialist, Redica Systems and Co-Chair, 2022 PDA Annual Meeting
Shelley M. Preslar, MBA, President and COO, Azzur Training Center Raleigh LLCand Co-Chair, 2022 PDA Annual Meeting

13:30 | Jeffrey C. Baker, PhD, Senior Fellow, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

13:55 | Donna Boyce, MS, Senior Vice President Global Regulatory Affairs, Pfizer Inc.

14:20 | Panel Discussion and Q&A

15:00 – 15:30 | Networking Break

15:30 – 17:00 | 15:30 – 17:00 | P2: Facing the Future
Moderator: Diane M. Paskiet, MS, Director of Scientific Affairs, West Pharmaceutical Services, Inc.

In January 2020, the first U.S. case of COVID-19 was confirmed, declared a pandemic in March, and by April, nearly half of the world's population was under lockdown. After two years, the return to normal is still uncertain. The pandemic experience typified the need to be prepared for serious unanticipated events. Advanced technologies to detect threats and rapidly develop novel medicines for timely access to life- saving medicines are critical for the future. This session will take a look at the significant strides made in the development of gene therapies, new molecule delivery systems and CRSIPR technology. Surveillance is another matter that will be addressed as it relates to zoonotic infectious diseases and emergence of new variants. 

15:30 | Benjamin Borgo, MS, PhD, MBA, Head of Portfolio Management and Product Development, MilliporeSigma

15:55 | Michael Brothers, PhD, Technical Program Manager/Principal Scientist, UES, Inc.

16:20 | Panel Discussion and Q&A

17:00 – 18:30 | Grand Opening Celebration in Exhibit Hall

Day 2

TUESDAY, 05 APRIL

08:30 – 10:00 | P3
Moderator: Amanda M. McFarland, MS, Senior Consultant, ValSource, Inc.

08:30 | The Challenges and Rewards Developing a World-Changing Pharmaceutical Innovative and Disrupted Patient-Focused Solution 
Donna Gulbinski,
Chief Quality and Regulatory Affairs Officer, Civica

08:55 | Robert Dean, MBA, Director/Team Leader, Advertising and Promotion, Merck & Co., Inc.

09:20 | Panel Discussion and Q&A

10:00 – 10:45 | Refreshment Break, Tech Talks, and Poster Presentations in Exhibit Hall

10:45 – 12:15 | Concurrent Sessions

ASEPTIC PROCESSING AND STERILIZATION

A1: Game Plan: Progress to the Next Stage of Contamination Control
Moderator: Amanda M. McFarland, MS, Senior Consultant, ValSource, Inc.

The 2022 revision of Annex 1 is setting the stage for a comprehensive contamination control strategy. To progress our organizations to the next level, new and innovative ways of thinking need to be employed. In this session, the speakers will provide insight into state-of-the-art approaches for advancing contamination control through comprehensive analytics and trending, strategies for reduced particulate recovery, and advanced cleaning techniques using physics.

10:45 | Strategies for Total Contamination Control in an Aseptic Environment
Sheba S. Zaman, Head of Product Specialists and Training Services, Novatek

11:05 | Contamination Control: A New Approach to the Reduction of 5-Micron Particles
Anne Marie Dixon-Heathman, MBA, President, Cleanroom Management Associates, Inc.

11:25 | Changing the Face of Contamination Control using Physics
Jeanne E. Moldenhauer, MS, Vice President, Excellent Pharma Consulting

11:45 | Panel Discussion and Q&A

BIOPHARMACEUTICALS AND BIOTECHNOLOGY

B1: Process Intensification: Increasing Yield per Unit
Moderator: Kakolie G. Banerjee, PhD, Senior Scientist, MilliporeSigma

Process intensification involves practices that improve product yield per unit, where “unit” could be time, consumables, resources, or footprint. Innovative upstream and downstream practices, such as use of perfusion bioreactors or continuous bioprocessing, can help achieve this goal. Benefits to intensified process include streamlined production, sustainability, reduced footprint and facility costs, and increased speed of production. In this session, we will be introduced to process intensification through an application using cell-based vaccine manufacturing. Subsequently, we will focus on best practices to validate the method using multivariate approach. Finally, we will learn about regulatory considerations. Each speaker will introduce us to implementation success stories and encourage a discussion on its application.

10:45 | Process Intensification of Cell-Based Vaccine Manufacturing
William G. Whitford, Life Science Strategic Solutions Leader, DPS Group

11:05 | Process Intensification: What's Possible When Declaring an Acceptable Use of Design Space
Jason J. Orloff, ChE, Principal Engineer and Statistician, PharmStat

11:25 | Continuous Bioprocessing: Regulatory Harmonization and Industry Best Practices – Quality and Regulatory Shifts Driving Implementation of Flexible Biopharmaceutical Manufacturing Systems
Janmeet Anant, Senior Regulatory Consultant, MilliporeSigma

11:45 | Panel Discussion and Q&A

MANUFACTURING SCIENCE

C1: Vaccine and Virus Products in Focus
Moderator: Guido Kremer-van der Kamp, Senior Consultant - Global BioPharm Center of Excellence, Merck Chemicals GmbH

The Covid-19 pandemic redirected both industry and public focus on vaccines and viral products. In this session, speakers will share best practices for container integrity important for vaccine distribution and quality by design principles applied in viral product development. As the development and production of vaccines need to be prepared for the future, participants will also learn how this can be achieved through implementing end-to-end digitization.

10:45 | Mitigating Risk to Container Closure Integrity of a COVID-19 Vaccine Product during Ultra-Cold Chain Storage and Distribution: A Best Practice Holistic Science-Based Approach
Derek I. Duncan, PhD, Director Product Line, Lighthouse Instruments
Michael T. Edey, Senior Principal Engineer, Pfizer Inc.

11:05 | Vaccine Development and Production Needs End-To-End Digitization to be Ready for the Next Pandemic
Stefan R. Kappeler, PhD, Senior Director Biopharma and Regulatory, Exyte Central Europe GmbH

11:25 | Quality by Design for Adeno-Associated Virus Products: A Framework
Paul Cashen, MSc, Senior Bioprocess Specialist, Pall Corporation

11:45 | Panel Discussion and Q&A

QUALITY AND REGULATORY

D1: Building Back Better: Innovative Options for Audits and Inspections
Moderator: Lori Dingledine, QC Lead- Microbial Control and Compendial Testing, Spark Therapeutics, Inc.

Innovative options for audits and inspections have become increasingly important due to the recent challenges brought about due to the pandemic. This session will focus on auditing in the “new normal” by providing details on various techniques and technologies for effective use in audits and inspections.

First, protocol-based site internal audits, including the pros and cons of this approach and how to implement protocol-based internal audit programs where appropriate, will be presented. Then, next-generation assessment technologies, such as automated harvesting data and artificial intelligence, can help auditors to zero-in on high patient safety risks, will be discussed. Finally, we will examine how onsite audits were affected during the pandemic, and how remote auditing was used throughout the industry.

10:45 | Protocol-Based Site Internal Audit Program: A Network-Wide Case Study
Mary E. Farbman, PhD, Executive Director, Global Quality Compliance, Merck & Co., Inc.

11:05 | Re-Imagine Audit: Bringing GxP Auditing into the Quality 4.0 Paradigm
Bruce Loxley, Senior GMP Compliance Advisor, GSK Vaccines

11:25 | The Link between Patient Safety and Pharmaceutical Auditing during a Pandemic
James M. Fries, CEO, Rx-360

11:45 | Panel Discussion and Q&A

12:15 – 13:45 | Networking Luncheon, Poster Presentations, and Tech Talks in Exhibit Hall

13:45 – 15:15 | Interest Groups

INTEREST GROUP

IG1: Biopharmaceutical Manufacturing
Leaders:

  • Peter J. Makowenskyj, MEng, Director of Design Consulting, G-CON Manufacturing, Inc.
  • Toni Manzano, PhD, CSO and Co-Founder, Aizon

Roundtable discussion to focus on Mobile Manufacturing Task Force.

INTEREST GROUP

IG2: Process Validation and Lyophilization

Process Validation IG Leader: Mauro Giusti, PhD, Advisor, Site External Network and President, PDA Italy Chapter, Eli Lilly Italia
Lyophilization IG Leader: Edward H. Trappler, President, Lyophilization Technology, Inc.

The Interest Group will be discussing the recently launched a survey on process validation approaches.

INTEREST GROUP

IG3: Quality Risk Management and GXP Auditing

QRM IG Leaders:

  • Amanda M. McFarland, MS, Senior Consultant, ValSource, Inc.
  • Eva M. Urban, MSc, Director QRM and Internal Audits, CSL Behring

GXP Auditing IG Leaders:

  • Gabriele Gori, ThermoFisher Scientific
  • Ghada N. Haddad, PhD, Executive Director, Global cGMP and Compliance Auditing Organization, Merck & Co., Inc.

We will discuss risk-based approaches to audits and inspection as well as have a panel discuss their experiences with remote inspections.

INTEREST GROUP

IG4: Visual Inspection
Leaders:

  • John G. Shabushnig, PhD, Principal Consultant, Insight Pharma Consulting, LLC
  • Rick J. Watson, Director, Sterile and Validation CoE, Merck & Co., Inc.

This will be a good opportunity to review changes in US and EU regulations, USP <1970> and Annex 1. Let’s discuss advances in the use of AI in automated visual inspection. The points-to-consider paper that our team is developing should be published at about this time.


15:15 – 16:00 | Refreshment Break, Passport Raffle, and Poster Presentations in Exhibit Hall

16:00 – 17:30 | Concurrent Sessions

ASEPTIC PROCESSING AND STERILIZATION

A2
Moderator: Shelley M. Preslar, MBA, President and COO, Azzur Training Center Raleigh LLC

16:00 | Blended Training Approach to Minimize Human Error in Biopharmaceutical Manufacturing
Benben Song, PhD, Global Product Manager, Pall Corporation

16:20 | Training is More than a Checkbox: Examples and Case Study in Training Effectiveness
George Bernstein, PhD, ChE, Managing Principal, Double Dragon Consulting

16:40 | Implementation of VR and AR Tools for Error Reduction
Humberto Vega, PhD, Sr. Director - Ext. Mfg. DP and Critical Materials, Bristol-Myers Squibb

17:00 | Panel Discussion and Q&A

BIOPHARMACEUTICALS AND BIOTECHNOLOGY

B2: New Technologies in Bioprocessing
Moderator: Kristin N. Valente, PhD, Director, Vaccine Technical Operations, Merck & Co., Inc.

The biopharmaceutical industry has evolved from traditional vaccines and therapeutic proteins to encompass a broad range of modalities, including mRNAs, cell therapies, and other advanced therapeutic medicinal products. All sectors of the industry are facing unprecedented pressure to increase agility and supply reliability, while reducing cost and speed-to-market. Technological evolution and introduction of novel technologies are required to meet these patient needs. In this session, we will share case studies of next generation technology implementation in both biologic drug product and cell therapy manufacturing processes. We will conclude by reviewing the shared vision from a cross-industry collaboration. 

16:00 | Challenges and Opportunities in Implementing Next-Generation Technologies for Drug Product Development and Manufacturing
Nitin Rathore, PhD, Executive Director, Amgen Inc.

16:20 | Advancing Cell Therapy Processing using Evolving Equipment Technologies
Aidan J. Harrington, PhD, Principal Consultant, DPS Group

16:40 | Technology Roadmap Phorum Industry Vision 2.0
Guido Kremer-van der Kamp, Senior Consultant - Global BioPharm Center of Excellence, Merck Chemicals GmbH

17:00 | Panel Discussion and Q&A

MANUFACTURING SCIENCE

C2: Transforming Product and Process Knowledge Acquisition to Become More Agile
Moderator: Mirko Gabriele, PhD, Senior Director, Global Sterile Strategy Technology and Innovation, ThermoFisher Scientific

Agility in development and supply chain builds on good clinical and commercial process design and realization. In this session, technologies that have the ability to change the way we work in manufacturing science will be presented. The goals of these technologies are to enhance the knowledge of interactions between equipment, process, and product.

16:00 | Structured Data Frameworks to Enable Digital Tech Transfer
Yashvinder Sabharwal, PhD, Chief Executive Officer, CherryCircle Software, Inc.

16:20 | The Digital Gap in the Pharma Industry: Effects in Patients and the Recipe to Succeed in the Journey
Toni  Manzano, PhD, CSO and Co-Founder, Aizon

16:40 | What If Sterile Product Processing Equipment Could “Talk”?: New Technology Facilitating Process-Product Communication
Mihaela Simianu, PhD, Executive Director, Merck & Co., Inc.

17:00 | Panel Discussion and Q&A

QUALITY AND REGULATORY

D2: Regulatory Intelligence in the Digital Age: Friend or Foe?
Moderator: Guido Kremer-van der Kamp, Senior Consultant - Global BioPharm Center of Excellence, Merck Chemicals GmbH

A blizzard of regulatory and quality information exists in the world of pharmaceutical manufacturing today, from both internal and external sources. This session will explain how to get the best internal data from personnel, will reimagine today’s regulatory intelligence process from start to finish, and will make the case for disrupting the status quo by driving to a single, globally harmonized Quality Management System.

16:00 | The Role of Psychological Safety in Reducing Human Error and Advancing Quality Management Maturity
James L. Vesper, PhD, MPH, Director, Learning Solutions, ValSource, Inc.

16:20 | Is Regulatory Intelligence Compatible with an Effective QMS?
Karen Ginsbury, MSc, Owner, PCI Pharmaceutical Consulting Israel

16:40 | Bringing Innovation to Regulatory Intelligence from Ideation to Success
Bob Chaplinsky, Head of Quality Management Systems, UCB Pharma SA
Michael de la Torre, CEO, Redica Systems

17:00 | Panel Discussion and Q&A

18:30 – 21:30 | Reception

Day 3

WEDNESDAY, 06 APRIL

08:30 – 10:00 | Interest Groups

INTEREST GROUP

IG5: Packaging Science
Leader: Susan M. Dounce, PhD, Director Commercial Technology Development, West Pharmaceutical Services, Inc.

The pandemic has changed the world of pharmaceutical packaging by bringing new, complex therapeutic entities into the mainstream seemingly overnight. The packaging science community, after spending decades mastering the containment of protein drugs have suddenly found themselves forging into uncharted and unfamiliar fields. With a panel of expert guest speakers, we will explore the inter-relationships and distinctions between RNA, gene and cell therapies. We will discuss how the therapeutic entities, their production processes and distribution, dictate containment requirements including and beyond cold storage. For example, in viral vector manufacturing, challenges arise due to the constant balance between processing small batch sizes and ensuring the valuable product makes it into the freezer within the time that the product is still stable. Finally, we will discuss where commonalities exist between antibody therapies and advanced therapies which would allow the substantial packaging knowledge amassed to date to be translated and leveraged in this rapidly changing landscape.

INTEREST GROUP

IG6: Microbiology/ Environmental Monitoring
Leader: Marc Glogovsky, MS, SM (NRCM), Senior Consultant - Microbiology, ValSource, Inc.

In this Interest Group Meeting, participants will discuss PDA Technical Report No. 13 Revised, (TR 13) Fundamentals of an Environmental Monitoring Program. There are many aspects of the revision that are coordinated with the expectations of the draft EU Annex 1.

INTEREST GROUP

IG7: Vaccines
Leaders:

  • Jane L. Halpern, PhD, Executive Director, IAVI
  • Sabrina Restrepo, PhD, Director, Global Vaccines Technical Operations, Merck & Co., Inc.

The ability to rapidly develop and manufacture mRNA vaccines with high efficacy against the SARS-CoV-2 virus is a tremendous public health accomplishment and has spurred widespread interest in mRNA vaccines for multiple infectious diseases and other indications. Other vaccine platforms and manufacturing technologies that have received less attention will also be important in the future to produce vaccines that can be rapidly manufactured at a low cost, with characteristics needed for easy storage and distribution.

In addition, the Vaccine Interest Group has recently completed a Technical Report “Strategies for Vaccines Development and Lifecycle Management”. The TR identified three areas of focus to support rapid development and effective vaccine lifecycle management (robust control strategies, comparability assessments and leveraging prior knowledge). These enablers have been incorporated into examples as appendices to the TR and will serve as the base for an interactive discussion.

INTEREST GROUP

IG8: Facilities and Engineering
Leaders:

  • Shelley M. Preslar, MBA, President and COO, Azzur Training Center Raleigh LLC
  • Joachim W. Regel, CA Bioprocess Systems Technical Specialist, Merck Chemicals GmbH

Vaccine Manufacturing: Case Study and Conversation on Increasing Speed-to-Market

The focus of this Interest Group will be to discuss different approaches and methodologies to increase our ability to cut down the time it takes to get to market. The session will begin with a case study that presents one approach to significantly reducing the time to market when building a Vaccine Fill/Finish Greenfield Facility. Then participants will discuss ideas to help the industry increase time-to-market for new or renovated facilities. 

Is there any value in having vendors work together up front to have equipment that more readily integrates with each other? What about equipment that can be incorporated into predesigned modular facilities? With your valuable input, we can determine if there is value in having a deeper discussion (i.e., potential PDA project) around this idea of integrating, coordinating, prefabricating, or even prequalifying critical components of a facility ahead of the construction.


10:00 – 10:45 | Refreshment Break, Tech Talks, and Poster Presentations in Exhibit Hall

10:45 – 12:15 | Concurrent Sessions

ASEPTIC PROCESSING AND STERILIZATION

A3: Cleanroom Manufacturing: A New Area Across Technology and Processes
Moderator: Mirko Gabriele, PhD, Senior Director, Global Sterile Strategy Technology and Innovation, ThermoFisher Scientific

Parenteral manufacturing is an expensive and time-consuming process, with several stringent requirements needed to guarantee quality and safety of the medicine produced.

The Covid-19 pandemic taught us that if from one side we need to preserve those quality and safety standards, from another we need to create an ecosystem able to react quickly to unforeseen events. This balance would give the pharmaceutical industry the ability to positively impact patients by offering new treatments faster.

The presenters in this session will highlight innovative technical solutions to achieve this balance. With general technical concepts, case studies, and lessons learned, the audience will leave with actionable knowledge ready to implement in companies.

10:45 | Rethinking Facility and Process Flexibilities: Cleanroom Infrastructures in a New Era of Therapies
Maik W. Jornitz, MSEng, CEO, G-CON Manufacturing, Inc.

11:05 | A 3P Model to Sustainable cGMP Cleaning
Elizabeth Rivera, Technical Services Manager, STERIS
Paul Lopolito, Sr. Technical Services Manager, STERIS

11:25 | Panel Discussion and Q&A

BIOPHARMACEUTICALS AND BIOTECHNOLOGY

B3: Navigating the Realm of Microbial/Rapid Technologies through Innovation and Collaboration
Moderator: Kenneth Paddock, Quality Director, Sterility Assurance, Baxter

The methodologies within the area of microbial growth detection and monitoring are constantly evolving based on the innovative technologies throughout the industry. In this session, the speakers will provide insight into modern microbial methods by discussing the validation process and regulatory acceptance for an automated colony counter utilizing a cross functional industry team, navigating speedbumps throughout implementation of a biofluorescent particle counting system, and a case study on rapid microbial detection for a purified water system.

10:45 | Automated Colony Counter: Successful Validation Experiences of an Eight Company User Group
Vaishali Shah, MS, Head of Quality Systems and Compliance, Kite Pharma, A Gilead Company
David L. Jones, PhD, Director of Industry Affairs, Rapid Micro Biosystems

11:05 | Industry Working Group Collaboration: Speedbump Navigation during the Implementation of a Bio-Fluorescent Particle Counting System
Philip A. Villari, MS, Associate Principal Scientist, Merck & Co., Inc.

11:25 | A Rapid Microbial Detection Technology to Identify Water Purification Failures in Real Time
Anthony C. Bevilacqua, PhD, Principal Scientist, Mettler-Toledo Thornton

11:45 | Panel Discussion and Q&A

MANUFACTURING SCIENCE

C3: Responding to Patient Needs
Moderator: Diane M. Paskiet, MS, Director of Scientific Affairs, West Pharmaceutical Services, Inc.

The aim of the 21st Century Cures Act is to enable the production of safe and effective medicines to improve patient experiences and outcomes. Patient-focused drug development is described in regulatory guidance as a multifaceted approach to link patient information with the product lifecycle. The connection of product design with manufacturing and timely access to medicines will also include the concepts for agile manufacturing. This session will focus on technologies designed for therapeutic outcomes and data capture across the manufacturing process up until the medicine is delivered to the patient. Presentations will cover biosensors for wearables, tracking critical assets to enhance manufacturing efficiencies, and preventing product mix-ups via primary container unit level tracking.

10:45 | Development of a Closed-Loop Wearable Injector System for Emergency Delivery of Naloxone
Alex Lyness, PhD, Senior Manager, Research and Technology, West Pharmaceutical Services, Inc.

11:05 | RFID Tracking for Asset Management, Compliance Support, and Process Improvement
Kevin J. McMurtrie, Global Business Manager, Documentation/Transfer Systems, Veltek Associates, Inc.
Doug Paradis, MS, Chief Technology Officer, Veltek Associates, Inc.

11:25 | Unit Level Syringe Identification and Traceability
Herve Soukiassian, Ass. Director Product Development PMO, BD

11:45 | Panel Discussion and Q&A

QUALITY AND REGULATORY

D3: Data Integrity Trends, Patterns, and Insights
Moderator: Susan J. Schniepp, Distinguished Fellow, Regulatory Compliance Associates Inc.

There is an enormous amount of data being collected today, but what does it all mean? In this session, attendees will hear insights and analyses from three experts who have reviewed industry data trends in the areas of data integrity, regulatory observations, and recalls. Through the understanding of this data, and what it means, our industry can improve its compliance position and continuously improve to produce safe and effective medicine for patients.

10:45 | Data Integrity Trends in 2021
Ulrich Köllisch, PhD, Manager Data Integrity, GxP-CC

11:05 | A Deep Dive into Industry-Wide Recall Data: Leveraging an Expert Ontology and AI to Uncover Patterns and Insights
Jerry L. Chapman, MBA, Senior GMP Quality Expert, Redica Systems

11:25 | Analyzing Global FDA 483 Observation Trends (2018-2020)
Steven Lynn, MS, Executive Vice President, Pharmaceuticals, Regulatory Compliance Associates Inc.

11:45 | Panel Discussion and Q&A

12:15 – 13:45 | Networking Luncheon, Poster Presentations, and Tech Talks in Exhibit Hall

13:45 – 15:15 | P4: The Future is Bright! Collaboration and Commitment Can Lead to Awe-Inspiring Results                                                                                             
Moderator: Shelley M. Preslar, MBA, President and COO, Azzur Training Center Raleigh LLC

Through unprecedented professional collaboration, tremendous progress has been achieved in technology and science over the past few years. We’ve come together to create effective tools to fight a global pandemic.  
 
Current global issues like supply chain issues and drug shortages unfortunately won’t come to an end tomorrow.  Consider the possibilities:
• What if formulations could be synthesized when and where they are needed?  
• What if companies could work together to overcome hesitation and adopt new technologies in commercial processes?  
 
This session will present impressive opportunities for the future, such as having pharmaceutical products available “on demand,” and a vision of potential outcomes if companies can move past the concept of wanting to be a “fast second” to adopting new technologies moving towards a future of “going first together”!

13:45 | De-Risking Biopharmaceutical Manufacturing Innovation by Going First Together
Kelvin H. Lee, PhD, Institute Director, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

14:10 | Medicine Manufacturing in the Hands of Clinicians: Pharmacy on Demand
John Lewin, PharmD, MBA, BCCCP, FASHP, FCCM, FNCS, Chief Medical Officer, On Demand Pharmaceuticals Inc.

14:35 | Panel Discussion and Q&A

15:05 | Closing Remarks from Co-Chairs and Adjournment

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

Book within the PDA block and be automatically entered to win a daily treat delivered to your hotel room!

A block of rooms have been reserved for meeting participants at the Hyatt Regency Dallas. The rate is $249 for single or double occupancy. Guestroom rates are subject to discounted resort fee ($20 per night) and state and local taxes.

Reservations must be secured by Friday, 04 March 2022. After this date, reservations can be made on a space-and-rate available basis only. Check-in time is 16:00; check-out time is 11:00.

To make reservations, individuals may click on the reservation link above or call the Hyatt Regency Dallas at +1 (214) 651-1234. Be sure to tell the reservationist that you are with the PDA Meeting to receive the PDA group rate.

Individual Cancellation

Please be aware that obtaining and canceling hotel reservations is the responsibility of the meeting registrant. Individuals will be responsible for payment of their own cancellation fees. The cancellation policy is 3 days in advance of arrival date, unless otherwise specified on your reservation information.


Located downtown next to an iconic Dallas landmark Reunion Tower, Hyatt Regency Dallas is a gateway to the best of the city. Live, work and be yourself at our inviting, contemporary hotel near the Dallas Convention Center and within walking distance of many tourist attractions, including Dealey Plaza and the Historic West End. Whether you are here to work or play, Hyatt Regency Dallas is designed to meet all of your needs.

How to Get Here
By Air Dallas/Fort Worth International Airport (DFW) is approximately 20 miles from the Hyatt Regency Dallas and all major carriers service this airport. Dallas Love Field Airport (DAL) is approximately 7 miles from the Hyatt Regency Dallas. Alaska Airlines, Delta and Southwest service this airport. Taxi fares from DFW are approximately $45-50 one way, not including tip. Taxi fares from DAL are approximately $20-25 one way, not including tip. App based rides are available to/from the airport.
By Car The Hyatt Regency Dallas is located at 300 Reunion Boulevard, Dallas, TX 75207. Valet Parking, operated by PMSI, is available at hotel entrance. In and out privileges for hotel guests only. Self-parking in the outdoor Radish Lot is conveniently located on the north end of the hotel at the intersection of Hotel Street and Reunion Boulevard West. In and out privileges for overnight guests only, operated by PMSI. Self Parking Overnight Guests Includes in & out privileges Daily Guest & Reunion Tower | $19 Radish Lot, 0–4 hours | $9 Radish Lot, 4–8 hours | $13 Radish Lot, 8-24 hours | $19 B-Lot, 0–4 | $7 B-Lot, 4–8 hours | $13 B-Lot, 8-24 hours | $19 Valet Parking Overnight Guests |$32 + tax 0–4 hours | $22 4–8 hours| $26 8–24 hours | $32